The Initial Therapeutic Response in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab Contributes to the Change of Liver Function during Treatment: A Multicenter Analysis
Rattachement africain : jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
INTRODUCTION: Therapeutic response in patients with unresectable hepatocellular carcinoma (HCC) receiving multikinase inhibitors is associated with changes in liver function. However, limited data are available for patients treated with atezolizumab plus bevacizumab (ATZ/BEV). METHODS: We retrospectively enrolled 151 patients with unresectable HCC who received ATZ/BEV as first-line systemic therapy. Liver function was assessed using albumin-bilirubin (ALBI) score at baseline (pre-ALBI) and 6 weeks after the initiation of ATZ/BEV (6W-ALBI). We evaluated the dynamic relationship between initial therapeutic response and changes in ALBI score (6W-ALBI - pre-ALBI), and examined the prognostic impact of pre-ALBI, 6W-ALBI, and ALBI score changes. RESULTS: Patients achieving an initial complete or partial response (CR+PR) showed a significantly higher rate of improvement in ALBI score from baseline to 6W after the initiation of ATZ/BEV than those with stable or progressive disease (SD+PD) at the initial treatment response (46% vs. 25%, respectively, p = 0.018). Among patients with baseline ALBI grade ≥2, changes in ALBI score differed significantly between the groups (median change: CR+PR vs. SD+PD, -0.03 vs. 0.18, respectively, p = 0.048). Time-dependent receiver operating characteristic analysis demonstrated 6W-ALBI had the best predictive ability for overall survival (OS) at 12 months after the ATZ/BEV initiation (optimal cutoff -1.95, area under the curve: 0.763). Using this cutoff, 6W-ALBI was independently associated with OS in multivariate analysis (hazard ratio: 2.40, p = 0.004). CONCLUSIONS: Initial therapeutic response to ATZ/BEV was associated with changes in liver function. The ALBI score during ATZ/BEV may serve as a prognostic indicator.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- The Initial Therapeutic Response in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab Contributes to the Change of Liver Function during Treatment: A Multicenter Analysis
- Date Crossref
- 11/05/2026
- Éditeur
- S. Karger AG
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Nagoya City University Department of Gastroenterology and Metabolism pays non établi dans la noticeUniversité ou école supérieure
-
Nagoya Medical Center pays non établi dans la noticeÉtablissement de santé
-
Japanese Red Cross Nagoya Daini Hospital pays non établi dans la noticeÉtablissement de santé
-
Gifu Prefectural Tajimi Hospital Department of Gastroenterology pays non établi dans la noticeÉtablissement de santé
-
Kasugai Municipal Hospital Department of Gastroenterology pays non établi dans la noticeÉtablissement de santé
-
Chukyo Hospital Department of Gastroenterology pays non établi dans la noticeÉtablissement de santé
-
Toyokawa City Hospital Department of Gastroenterology pays non établi dans la noticeÉtablissement de santé
-
Nagasaki Rousai Hospital pays non établi dans la noticeÉtablissement de santé
-
Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital Department of Gastroenterology pays non établi dans la noticeÉtablissement de santé
-
Asahi Rousai Hospital Department of Gastroenterology pays non établi dans la noticeÉtablissement de santé
Department of Gastroenterology and Metabolism — Nagoya City University, Nagoya Medical Center et Japanese Red Cross Nagoya Daini Hospital, avec 7 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.